



Humoral and Cellular Response after Vaccination

Guest Editors:

Dr. Adrian Onu

1. "Cantacuzino" Institute, 050096
Bucharest, Romania
2. Faculty of Pharmacy, Titu
Maiorescu University, 040317
Bucharest, Romania

Dr. Iuliana Caras

Cantacuzino, National Medical-
Military Institute for Research and
Development, 050096 Bucharest,
Romania

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editors

Dear Colleagues,

Efficient vaccination relies on inducing a robust adaptive immune response, both cellular and humoral, each playing a specific role in preventing or controlling infection. The challenge in developing an effective vaccine lies in finding the right balance between the different types of immune response required. To evaluate a vaccine, a range of methods have been developed. Immunization markers are constantly evolving, and sometimes newer markers from large data sets, identified through principal component analysis, replace traditional ones. In addition to the polarization of the immune response, the impact of immunization on innate immunity (trained immunity) calls for the use of additional instruments and concepts to assess vaccine effectiveness.

This special issue seeks to provide an overview of the current methodology for evaluating vaccines, from the design phase to clinical trials. The proposed articles aim to offer relevant insights into these concepts in the field of modern vaccination.

Dr. Adrian Onu
Dr. Iuliana Caras
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com